Results 181 to 190 of about 126,024 (329)

Prospects for non-immunological molecular therapeutics in melanoma [PDF]

, 2010
In 2006 there were 60,000 new cases of cutaneous melanoma in the European Union and 13,000 deaths (www.europeancancerleagues.org). Currently available systemic treatment options for metastatic melanoma, including both cytotoxic and immunologic therapies,
Crown, John, Eustace, Alexander J., Mahgoub, Thamir, O'Donovan, Norma, Tryfonopoulos, Dimitrios   +4 more
core  

Impact of Early‐Line Systemic Therapies on Liver Function in Hepatocellular Carcinoma: Longitudinal Change of ALBI Score and Ammonia Level With and Without Anti‐VEGF Agents

Hepatology Research, EarlyView.
ABSTRACT Background and Aim Anti–vascular endothelial growth factor (VEGF) agents are widely used for hepatocellular carcinoma (HCC); inhibition of VEGF‐mediated liver regeneration may compromise hepatic reserve. We investigated the impact of anti‐VEGF therapy on liver function and risk factors for deterioration of albumin–bilirubin (ALBI) score during
Naoshi Nishida, Kazuomi Ueshima, Tomoko Aoki, Takuya Matsubara, Naoya Omaru, Natsuki Okai, Masahiro Morita, Hirokazu Chishina, Masahiro Takita, Satoru Hagiwara, Yasunori Minami, Masatoshi Kudo   +11 more
wiley   +1 more source

Primary and Secondary Grzybowski’s Generalized Eruptive Keratoacanthoma: A New Perspective on Management, Clinical Features, and Prognosis

International Journal of Dermatology, EarlyView.
ABSTRACT Grzybowski's generalized eruptive keratoacanthoma (GEKA) is a rare variant of keratoacanthomas, characterized by hundreds to thousands of lesions, accompanied by pruritus, mucosal involvement, and comorbidities. Our aim was to analyze the clinical presentation, associated comorbidities, treatment strategies, and outcomes of GEKA.
Nicholas Florin Kormos, Carina Maria Petrenciu, Alin Stefan Vizitiu, Raluca Ghețe, Umer Nadir, Adrian Lucian Baican, Stanislav N. Tolkachjov   +6 more
wiley   +1 more source

Systemic Therapy in Endometrial Cancer: Recent Advances. [PDF]

, 2013
Endometrial cancer is a chemosensitive disease. Studies have established a clear benefit of chemotherapy in advanced stages and trials are ongoing to define its role in early stages as well.
Bhise, R, Guru Prasad B, B, Kundargi, R, Lakshmaia, KC, Purohit, S, Shetty, R   +5 more
core   +1 more source

Effectiveness of Sorafenib in Patients with Transcatheter Arterial Chemoembolization (TACE) Refractory and Intermediate-Stage Hepatocellular Carcinoma [PDF]

, 2015
Tadaaki Arizumi, Kazuomi Ueshima, Tomohiro Minami, Masashi Kono, Hirokazu Chishina, Masahiro Takita, Satoshi Kitai, Tatsuo Inoue, Norihisa Yada, Satoru Hagiwara, Yasunori Minami, Toshiharu Sakurai, Naoshi Nishida, Masatoshi Kudo   +13 more
openalex   +1 more source

Hand–Foot Syndrome to Sorafenib

, 2022
Sherin Dominic, Vijay Aithal
openalex   +1 more source

Harnessing blue light photobiomodulation for cancer therapy: Evidence from a systematic review

Photochemistry and Photobiology, EarlyView.
Conventional treatments for various types of cancer are often associated with tumor recurrence and aggressiveness. Photobiomodulation with blue light (BL; 450–470 nm) emerges as a promising alternative with antitumor effects. This systematic review, with 37 in vitro and in vivo studies from 2002 to 2024, revealed that BL reduces cell viability ...
Bárbara Evelyn Santos de Lima, Rebeca Barros Nascimento, Ana Paula Mariano Santos Ginez, Maria Stella Moreira, Rebeca Boltes Cecatto, Rodrigo Labat Marcos, Maria Fernanda Setúbal Destro Rodrigues   +6 more
wiley   +1 more source

Modified reaction condition to achieve high yield and cost efficient hazardous free synthesis of Sorafenib API

, 2018
Shiva Rama Krishna Samala, B Srinivasa Rao, Kishore Gokavarapu, Sarita Gokavarapu, Sunil Gandhi   +4 more
openalex   +1 more source

Schedule-dependent antitumor effects of 5-fluorouracil combined with sorafenib in hepatocellular carcinoma [PDF]

, 2013
Li-fen Deng, Zhenggang Ren, Qingan Jia, Wei‐Zhong Wu, Hujia Shen, Yanhong Wang   +5 more
openalex   +1 more source

Head‐to‐head comparison of TKI and CPI first‐line treatment strategies in advanced renal cell carcinoma—Real‐world data from the German research platform CARAT

International Journal of Cancer, Volume 158, Issue 6, Page 1690-1702, 15 March 2026.
What's new? The current standard of care for locally advanced or metastatic renal cell carcinoma (aRCC) is either a combination of two immune checkpoint inhibitors (CPI) or a CPI plus a tyrosine kinase inhibitor (TKI). Here, the authors simulate a head‐to‐head trial comparing the real‐world effectiveness of these combination therapies with TKI ...
Peter J. Goebell, Martin Bögemann, Arnd Nusch, Viktor Grünwald, Lothar Müller, Eyck von der Heyde, Uwe M. Martens, Carolin Lennartz, Michaela Koska, Karin Potthoff, Anja Kaiser‐Osterhues, Carsten Grüllich, Michael Staehler, Martina Jänicke, Dominik Marschner, the CARAT Registry Group   +15 more
wiley   +1 more source